Cosmetic dentistry is increasingly becoming an issue of concern to patients who hope to improve their smile. A systematic and comprehensive dentofacial analysis must be performed before commencing esthetic treatment. Several computer software programs have been developed for digital smile design (DSD) to assist clinicians in this process. This article compares DSD programs commonly used in cosmetic dentistry and their ability to assess esthetic parameters. A literature review was performed of current dentofacial aesthetic parameters and clinical applications of computer technology to assess facial, dentogingival and dental esthetics. Eight DSD programs (Photoshop CS6, Keynote, Planmeca Romexis Smile Design, Cerec SW 4.2, Aesthetic Digital Smile Design, Smile Designer Pro, DSD App and VisagiSMile) were compared. Photoshop, Keynote and Aesthetic Digital Smile Design included the largest number of esthetic analysis parameters. Other studied DSD programs presented deficiencies in their ability to analyze facial esthetic parameters but included comprehensive dentogingival and dental esthetic functions. The DSD App, Planmeca Romexis Smile Design, and Cerec SW 4.2 were able to perform 3D analysis; furthermore, Cerec SW 4.2 and PRSD could be used jointly with CAD/CAM. The DSD App and Smile Designer Pro are available as mobile phone applications. It can be concluded that despite the fact that they were not specifically designed for dental diagnosis, Photoshop CS6 and Keynote provide a more comprehensive smile analysis than most specialized DSD programs. However, other program functions should also be considered when deciding which DSD program is applicable to individual clinical setups.
Ceramide and sphingosine are important interconvertible sphingolipid metabolites which govern various signaling pathways related to different aspects of cell survival and senescence. The conversion of ceramide into sphingosine is mediated by ceramidases. Altogether, five human ceramidases—named acid ceramidase, neutral ceramidase, alkaline ceramidase 1, alkaline ceramidase 2, and alkaline ceramidase 3—have been identified as having maximal activities in acidic, neutral, and alkaline environments, respectively. All five ceramidases have received increased attention for their implications in various diseases, including cancer, Alzheimer’s disease, and Farber disease. Furthermore, the potential anti-inflammatory and anti-apoptotic effects of ceramidases in host cells exposed to pathogenic bacteria and viruses have also been demonstrated. While ceramidases have been a subject of study in recent decades, our knowledge of their pathophysiology remains limited. Thus, this review provides a critical evaluation and interpretive analysis of existing literature on the role of acid, neutral, and alkaline ceramidases in relation to human health and various diseases, including cancer, neurodegenerative diseases, and infectious diseases. In addition, the essential impact of ceramidases on tissue regeneration, as well as their usefulness in enzyme replacement therapy, is also discussed.
1 March 2021 in Biochemical and Biophysical Research Communications
Emerging studies indicate that intracellular eukaryotic ceramide species directly activate cathepsin B (CatB), a lysosomal‐cysteine‐protease, in the cytoplasm of osteoclast precursors (OCPs) leading to elevated RANKL‐mediated osteoclastogenesis and inflammatory osteolysis. However, the possible impact of CatB on osteoclastogenesis elevated by non‐eukaryotic ceramides is largely unknown. It was reported that a novel class of phosphoglycerol dihydroceramide (PGDHC), produced by the key periodontal pathogen Porphyromonas gingivalis upregulated RANKL‐mediated osteoclastogenesis in vitro and in vivo. Therefore, the aim of this study was to evaluate a crosstalk between host CatB and non‐eukaryotic PGDHC on the promotion of osteoclastogenesis. According to a pulldown assay, high affinity between PGDHC and CatB was observed in RANKL‐stimulated RAW264.7 cells in vitro. It was also demonstrated that PGDHC promotes enzymatic activity of recombinant CatB protein ex vivo and in RANKL‐stimulated osteoclast precursors in vitro. Furthermore, no or little effect of PGDHC on the RANKL‐primed osteoclastogenesis was observed in male and female CatB‐knock out mice compared with their wild type counterparts. Altogether, these findings demonstrate that bacterial dihydroceramides produced by P. gingivalis elevate RANKL‐primed osteoclastogenesis via direct activation of intracellular CatB in OCPs.